靶向METTL3干预核因子RORA/RORγt抑制致病性Th17细胞分化并减轻狼疮性肾炎肾损伤
该研究探讨METTL3在狼疮性肾炎(LN)致病性Th17细胞分化中的作用及靶向干预的治疗潜力。在LN患者和MRL/lpr小鼠肾脏中CD4+ T细胞和致病性Th17细胞浸润增高,伴METTL3高表达;METTL3通过增加RORA转录本m6A修饰稳定RORA表达及以m6A非依赖方式上调RORC表达促进Th17分化,特异性抑制CD4+ T细胞METTL3可减轻肾损伤。
要点
- LN患者和MRL/lpr小鼠肾脏CD4+ T细胞与致病性Th17细胞浸润增高,伴METTL3高表达
- METTL3通过m6A修饰稳定RORA及m6A非依赖上调RORC两条途径促进致病性Th17分化
- CD4+ T细胞特异性抑制METTL3可抑制致病性Th17分化、阻断肾炎进展并减轻肾损伤
核心结论
- METTL3可能作为狼疮性肾炎精准治疗的新靶点。
研究设计与样本
- 研究采用MRL/lpr和pristane诱导的BALB/c狼疮小鼠模型,分别接受STM2457或标准药物八周后收集组织、血液和尿液。
- 收集LN患者及对照者的血液和肾脏穿刺活检标本,结合多组学分析及细胞、分子和影像学实验评估免疫病理与治疗效果。
主要发现
- LN患者和MRL/lpr小鼠肾脏中CD4+ T细胞和致病性Th17细胞浸润高于对照,伴METTL3表达升高。
- METTL3上调促进Th17细胞分化并介导肾损伤。
- 机制上,METTL3通过增加RORA转录本m6A修饰稳定RORA表达,并以m6A非依赖方式通过升高Smad2和STAT3磷酸化水平增强RORC表达。
- CD4+ T细胞中特异性抑制METTL3可抑制致病性Th17细胞分化,阻断肾炎发展并减轻肾损伤。
临床怎么用
- 靶向METTL3可能通过抑制致病性Th17细胞分化减轻狼疮性肾炎肾损伤,为精准治疗提供新思路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Abnormal differentiation of T helper 17 (Th17) cells is an important mechanism underlying lupus nephritis (LN) pathogenesis. However, its driving mechanism remains unclear. Modification of m6A, the most dominant RNA modification, is a novel mechanism for regulating cell phenotypes and functions, with methyltransferase-like 3 (METTL3) being an important methyltransferase. Nonetheless, whether m6A modification participates in the regulation of Th17 cell differentiation in patients with LN has not been reported. Our study investigates the effect of targeting METTL3 on Th17 cell infiltration, assesses its potential therapeutic role in LN, and further clarifies underlying mechanisms. METHODS: Murine LN models (MRL/lpr, pristane-induced BALB/c) received STM2457 or standard drugs. Tissues, blood, and urine were collected after eight-week regimens. Blood and kidney needle biopsy specimens were collected from patients with LN along with control individuals. Multi-omic analyses along with cellular, molecular, and imaging assays assessed immunopathology and therapeutic effects. RESULTS: The infiltration of CD4+ T cells and pathogenic Th17 cells in the kidneys of patients with LN and MRL/lpr mice were higher than those in control individuals, accompanied by high METTL3 expression. METTL3 upregulation promoted differentiation of Th17 cells and mediated kidney injury. Mechanistic investigations revealed that METTL3 promotes pathogenic Th17 cell differentiation via two pathways. First, by increasing m6A modification of nuclear factor RAR-related orphan receptor (RORA) transcripts, thereby stabilizing them and enhancing RORA expression. Second, by augmenting RAR-related orphan receptor C (RORC) expression through elevating Smad2 and STAT3 phosphorylation levels in an m6A-independent manner. Furthermore, specific inhibition of METTL3 in CD4+ T cells can suppress the differentiation of pathogenic Th17 cells, thereby blocking the development of nephritis and alleviating kidney damage. CONCLUSIONS: METTL3 may serve as a new therapeutic target for precise LN treatment.
引用
- Xia X, Long C, Chen W, et al. METTL3-targeted intervention on nuclear factors RORA/RORγt suppresses pathogenic T helper 17 cell differentiation and alleviates kidney damage in lupus nephritis. Kidney Int. 2026. PMID: 41722729. doi:10.1016/j.kint.2026.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。